Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Asset Writedowns and Impairment (2023 - 2025)

Historic Asset Writedowns and Impairment for Spero Therapeutics (SPRO) over the last 2 years, with Q3 2025 value amounting to $600000.0.

  • Spero Therapeutics' Asset Writedowns and Impairment changed N/A to $600000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $600000.0, marking a year-over-year decrease of 8869.2%. This contributed to the annual value of $5.3 million for FY2023, which is 73559.06% up from last year.
  • As of Q3 2025, Spero Therapeutics' Asset Writedowns and Impairment stood at $600000.0.
  • In the past 5 years, Spero Therapeutics' Asset Writedowns and Impairment ranged from a high of $5.3 million in Q3 2023 and a low of $600000.0 during Q3 2025